INTRODUCTION
Diuron [3-(3,4-dichlorophenyl)-1,1-dimethylurea] is a substituted phenylurea compound widely used as a systemic herbicide and antifouling biocide. Due to its extremely slow breakdown in water, diuron is highly persistent in the environment (Madhum and Freed, 1987) . Its wide use in agriculture leads to pollution of the freshwaters by soil leaching, and it has been detected in marinas and coastal areas in the United Kingdom (Thomas et al., 2001 ), Germany (Lamoree et al., 2002) and Japan (Okamura et al., 2003) . The European Water Framework Directive (WFD) includes diuron as a priority substance (PS) which represents a significant risk to or through the European aquatic environment (European Commission, 2001 ). The United States Environmental Protection Agency also reported diuron on the list of substances considered contaminants of drinking water since 1998 (USEPA, 2005) .
Diuron has been classified as a slightly hazardous (toxicity class III) pesticide by WHO.
The acute oral LD 50 for male rats is 4721 mg/kg. Diuron has been characterized as a "known/likely" human carcinogen based on urinary bladder carcinomas in both sexes of the Wister rat, kidney carcinomas in the male rat (a rare tumor) and mammary gland carcinomas in the female NMRI mouse (USEPA, 2004) . Moreover, diuron also showed in vivo mutagenic activity in Swiss mice by the bone marrow micronucleus test (Agrawal et al., 1996) .
The environmental impact of diuron transformations was recently reviewed by Giacomazzi and Cochet (2004) . Among the detected transformation products at least dichloroaniline, the principal product of biodegradation, exhibited a higher toxicity and persistence in soil, water and groundwater. Demethyldiuron had higher non-target toxicity than diuron (Tixier et al., 2000) .
Only a few studies on diuron metabolism in mammals have been published. In metabolic studies of rats and dogs, N-(3,4-dichlorophenyl) urea was the predominant DMD #16295 5 metabolite in the urine. Small amounts of N- (3,4-dichlorophenyl)-N-methylurea, 3,4- dichloroaniline, 3,4-dichlorophenol and unchanged diuron were detected (Hodge et al., 1967) .
In a human postmortem case diuron and its demethylated, didemethylated and hydroxylated metabolites were identified in plasma and urine. Diuron levels as high as 5 mg/L in plasma and 3 mg/L in urine have been found, moreover, a rough estimate of the total concentration of diuron plus metabolites in plasma was found to be near 100 mg/L, resulting in as estimated uptake of at least several grams (Verheij et al., 1989) . On the other hand, in a hospitalized case, diuron was completely metabolized mainly via demethylation (2.0 and 180 mg/L) and didemethylation (70 and 68 mg/L) in blood and urine, respectively. In addition urine extracts contained 36 mg/L hydroxyphenyldiuron and 0.2 mg/L 3,4-dichloroaniline (Van Boven et al., 1990 ).
The cytochrome P450 (CYP) enzymes are important in the metabolism of various endogenous substrates as well as a wide range of xenobiotics. During the last few years several papers on the role of CYPs in the metabolism of a wide variety of pesticides have appeared (Usmani et al., 2004; Mutch and Williams, 2006; Abass et al., 2007a,b) . On the other hand, only limited data are available concerning diuron biotransformation by mammalian CYPs. Suzuki and Casida (1981) reported that mouse liver microsomal oxidase converted diuron into seven metabolites. The major metabolite was N-demethyldiuron, and minor amounts of three hydroxymethyl metabolites and two formamides were detected by thin layer chromatography.
The studies on the diuron biotransformations in different mammalian species including human are vital for chemical risk assessment purposes by the application of the toxicokinetics default uncertainty/safety factors for interspecies differences and interindividual variation (Renwick and Lazarus, 1998) . However, there is no data concerning the mammalian hepatic enzyme kinetics of diuron, neither the contribution of CYP isoforms to its metabolic pathways DMD #16295 6 nor the inhibitory interaction with different human liver CYP enzymes. The current study was conducted 1) to identify and quantify potential diuron metabolites by human liver homogenates and human, mouse, rat, dog, monkey, minipig, and rabbit liver microsomes in vitro, 2) to assess the relative contributions of human CYPs responsible for diuron metabolism, 3) to quantify diuron metabolites by individual human liver microsomes, and 4) to examine the inhibitory interactions with different human liver CYP enzymes.
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MATERIALS AND METHODS
Chemicals. , N,N'-bis(3,4-dichlorophenyl)urea and 3-(3,4-dichlorophenyl)-1-methylurea were purchased from Dr.
Ehrenstorfer (Augsburg, Germany), and 3,4-dichloroaniline, bis(p-chlorophenyl)urea and 3-(4-chlorophenyl) methyl urea from ChemService (West Chester, PA). Midazolam was a kind gift from F. Hoffmann La Roche (Basel, Switzerland) and omeprazole from Astra Zeneca (Mölndal, Sweden). HPLC-grade solvents were obtained from Rathburn (Walkerburn, UK) and Labscan (Dublin, Ireland). All other chemicals used were from the Sigma Chemical Company (St. Louis, MO) and were of the highest purity available. Water was freshly prepared in-house with the Simplicity 185 (Millipore S.A., Molsheim, France) water purification system and was UP grade (ultra pure, 18.2 M Ω ).
Human liver homogenates, mammalian liver microsomes and cDNA-expressed human P450 enzymes. Human liver samples used in this study were obtained from the University Hospital of Oulu as surplus from kidney transplantation donors. The collection of surplus tissue was approved by the Ethics Committee of the Medical Faculty of the University of Oulu, Finland. All liver samples were of Caucasian race including 4 female and 6 male between age of 21 and 62. Intracerebral hemorrhage was the primary cause of death. Detailed characteristics of the liver samples are presented in our previous publication (Abass et al., 2007a) . The livers were transferred to ice immediately after the surgical excision and cut into pieces, snap-frozen in liquid nitrogen and stored at -80° C. Human liver homogenate was prepared from livers of ten individuals by homogenizing liver tissue in four volumes of 0.1 M phosphate buffer (pH 7.4), i.e. the homogenate contained 200 mg of hepatic tissue/ml. Male DBA/2 mouse, Sprague-Dawley rat, Beagle dog, Cynomolgus monkey, Göttingen minipig, and New Zealand white rabbit liver samples were obtained after approval of the Ethics Committee of the University of Oulu, Finland. All microsomes were prepared by standard DMD #16295 8 differential ultracentrifugation (Pelkonen et al., 1974) . The final microsomal pellet was suspended in 100 mM phosphate buffer, pH 7.4. Protein content was determined by the Bradford method (Bradford, 1976) . Baculovirus-insect cell expressed human CYPs (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 and 3A5) were purchased from BD Biosciences Discovery Labware (Bedford, MA). To measure the production of potential metabolites, human liver homogenates incubations were prepared containing the same final diuron concentrations as the microsomal incubations. In addition to 40 µL of human liver homogenates (contains app. 0.14 mg microsomal protein), the other components in homogenate incubates were 5 mM uridine 5`-diphosphoglucuronic acid (UDPGA), 1 mM glutathione, 1.2 mM adenosine-3`-phosphate-5`-phosphosulfate (PAPS) and 1 mM NADPH in a final volume of 200 µl of 0.1 M phosphate buffer (pH 7.4). The incubations and analytical method were similar to the microsomal incubations.
In
To measure the main diuron metabolites of recombinantly expressed CYP enzymes, the standard incubation mixture (200 µl) contained 0.1 M phosphate buffer (pH 7.4), 1 mM DMD #16295 9 NADPH, 100 µM diuron and recombinantly expressed CYP enzymes (50 pmol CYP per ml).
Incubations were carried out according to the manufacturer's instructions. Shortly, the reaction was started by adding recombinant enzymes to the preincubated reaction mixture (2 min at +37 °C), mixed gently and incubated for 30 min at +37 °C in an incubator block without agitation. Otherwise, the incubation protocol and analytical method were similar to microsomal incubations. 
by Eadie-Hofstee plots (V versus V/S). N-demethyldiuron formations were
catalyzed by one or more microsomal enzymes with similar kinetics (data not illustrated). The kinetic parameters for the diuron metabolism in liver microsomes were determined by using a wide concentration range (1 µM -400 µM) of diuron. The results are presented in Table 2 . 3A5) showed that all tested CYPs had detectable diuron N-demethylation activities. The kinetic parameters for the rCYPs were determined and are shown in Table 3 .
CYP2C19 showed the highest affinity toward diuron demethylation, corresponding to the lowest K m value, whereas the lowest affinity was observed for CYP2C8. V max values for CYP1A1 and CYP1A2 were the highest (215.6 and 173.4), while the V max of CYP2C8 was the lowest (1.07 nmol N-demethyldiuron/ (nmol P450*min)). V max /K m values illustrated that CYP1A1, CYP1A2 and CYP2C19 were the most efficient rCYPs for diuron transformation to N-demethyldiuron (2395.6, 1968.2 and 1696.7 µl/(nmol P450*min), respectively), whereas CYP2C8 was the least efficient (6.2 µl/(nmol P450*min)).
Taking into account the average human hepatic microsomal protein amounts of CYPs were calculated and are shown in Table 3 . 
Quantification of diuron metabolism in vitro by
DISCUSSION
Diuron has been reported to be metabolized in vivo in rats, dogs (Hodge et al., 1967) and humans (Van Boven et al., 1990; Verheij et al., 1989) via demethylation, didemethylation and hydroxylation. In addition mouse liver microsomes metabolized diuron mainly to demethyldiuron (Suzuki and Casida, 1981) . In the present study, the only diuron biotransformation pathway observed in the seven mammalian hepatic microsomes and human partial conversion to N-demethyldiuron (Suzuki and Casida, 1981) . In a human postmortem case, the hydroxymethyl metabolite was detected from a chemical ionization (CI) spectrum using LC/MS with a moving-belt interface, even though it was poorly separated from the didemethylation metabolite and its amount was small. However, in our study, the hydroxylated metabolites were not detected in any species even though they were searched from extracted mass chromatograms. If N-demethylation proceeds via the N-hydroxymethyl intermediate, its concentration may be too small to detect or it may be too unstable even for electrospray ionization.
N-demethyldiuron was detected and quantified in all tested liver preparations from different mammalian species. Because the concentrations of diuron and its N-demethylation DMD #16295
18 metabolite were decreasing especially at the lowest diuron concentration, further metabolism could have happened in MLM, DLM, MonLM and HLH, although we did not detect any metabolites. In electrospray ionization, all of the compound would not necessarily ionize and consequently these metabolites would not be detected. In some dogs diuron was reported to be metabolized in vivo to phenolic compounds which are frequently excreted as sulfate and glucuronide conjugates (Hodge et al., 1967) . Even if we were not able to detect any phase II metabolites, it is possible that the formation of 'MS-invisible' metabolites could partially explain the rapid disappearances of both diuron and N-demethyldiuron at least in dogs.
An Animal to human efficiency comparison revealed that DLM metabolized diuron 2.3-fold more than HLM, while the rat had the smallest value (0.43-fold). Differences in efficiencies between rat, minipig and human liver microsomes have been reported by Lang et al. (Lang et al., 1996) in the metabolism of triazine herbicides such as atrazine and ametryn.
Also with other pesticides such as chlorpyrifos (organophosphorus insecticide) and carbofuran (carbamate insecticide), human liver microsomes showed lower rates of metabolism than mouse and rat liver microsomes (Tang et al., 2001; Usmani et al., 2004) .
The interspecies differences in N-demethyldiuron formation as a function of time correlated with the variation in kinetic parameters. DLM was the most active mammalian microsomes in diuron biotransformation over the time and concentrations used. However, in the 5 and 25 µM diuron incubations, N-demethyldiuron concentrations were lower because of a massive disappearance of the parent compound. Also kinetic data demonstrated that DLM had the highest capacity and efficiency for diuron transformation. On the other hand, RLM was the least active microsomes in diuron transformation over time and had the lowest efficiency. HLM displayed the highest affinity and lowest capacity.
All tested recombinant CYPs were able to metabolize diuron to N-demethyldiuron.
Kinetic characterization showed that diuron metabolism to N-demethyldiuron was one-phasic, DMD #16295
19 in other words, it can be described as involving one active site or several sites with similar enzyme kinetic characteristics. CYP1A1, CYP1A2, CYP2C19, CYP2D6, CYP2B6 and CYP3A4 were relatively active in N-demethyldiuron formation. Based on intrinsic clearance values and human hepatic microsomal P450 isoenzyme concentrations, the relative contribution of CYP1A2 to diuron N-demethylation was estimated to be 60% due to both high intrinsic clearance and average amount. CYP2C19 was estimated to contribute 14 % and CYP3A4 13 %. Although CYP1A1 had the highest intrinsic clearance value, its contribution is probably negligible because the amount of CYP1A1 in the human liver is very small (Rendic and Di Carlo, 1997) . However, the contribution of CYP1A1 in extrahepatic tissues may be considerable in special circumstances. The rank order of the relative contributions of hepatic P450 enzymes was CYP1A2 > CYP2C19 > CYP3A4 > CYP2D6 > CYP2B6 > CYP2A6, CYP2C9 > CYP2E1 > CYP2C8.
It is an established fact that xenobiotic metabolizing P450 enzyme activities display a large interindividual variation (Pelkonen et al., 1998) . Also in this study, specific activities of CYP isoform-catalyzed reactions in microsomes from ten human livers displayed high
variability. An individual with the highest levels of both CYP1A2 and CYP2C19 (HL28) had the highest N-demethyldiuron formation, and the reverse was true for an individual (HL31) who had the lowest levels of both isoforms. Moreover, the correlation studies in individual humans suggested that at least those individuals with a high CYP1A2 content may be able to metabolize diuron more efficiently. A high correlation with CYP2C8 activity was probably an artifact, because CYP2C8 is very poor in N-demethylating diuron.
An extensive in vitro screening of potential CYP-based interactions indicated that diuron inhibited CYP1A1/2 enzymes in HLM relatively potently, with an IC 50 value of 4.1 µM. The corresponding values were higher than 100 µM for the other tested CYPs. It is not surprising that diuron inhibited CYP1A1/2, since these were CYP isoforms with a relatively DMD #16295 20 low Km value for diuron N-demethylation. Very little has been reported about the potential interaction of diuron with other CYP enzyme activities. Diuron did not affect the CYP19-associated aromatase activity in human placental microsomes in vitro (Vinggaard et al., 2000) .
The 100-fold uncertainty factor (UF) is used to convert a no-observed-adverse-effect level (NOEAL) from an animal toxicity study to a safe value for human intake. Furthermore, this UF has to allow for a 10-fold interspecies difference (which is subdivided into a factor of 10 0.6 (4.0) for toxicokinetics and 10 0.4 (2.5) for toxicodynamics) and a 10-fold interindividual variation (which is divided equally into two subfactors each of 10 0.5 (3.16)) (WHO/IPCS, 2005) . In our results the highest uncertainty factor for animal to human differences in toxicokinetics (AK UF ) was 2.3-fold. In addition the uncertainty factor for human variability in toxicokinetics (HK UF ) was 1.5-fold, as defined by Renwick and Lazarus (Renwick and Lazarus, 1998) as a variation between the mean and the highest value. It has to be stressed here that we measured only the hepatic metabolism of diuron, but on the other hand, metabolism is usually the most important factor contributing to interindividual and interspecies differences in toxicokinetics.
In order to obtain quantitative toxicokinetic data for comparison between individuals or between animals and human, human data are needed (Falk-Filipsson et al., in press ).
Moreover, risk assessment has to be carried out using quantitative chemical-specific data which will influence the toxicokinetics and toxicodynamics (Walton et al., 2001) . Our studies, although restricted to metabolic data by human and animal liver preparations, provide important quantitative diuron specific data for risk assessment, which suggest that both the interspecies difference and interindividual variation values are within the standard toxicokinetic default uncertainty/safety factors. These results will be valuable in further defining the risks associated with exposure to diuron.
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In conclusion, metabolic route, kinetic and interactions studies showed that the diuron biotransformation pathway involved the demethylation at the terminal nitrogen-atom in seven different mammalian hepatic microsomes and in human liver homogenates, No phase II metabolites were observed. All tested rCYPs catalyzed diuron N-demethylation. The most important human liver CYPs were CYP1A2, CYP2C19 and CYP3A4. Diuron was a relatively potent inhibitor of human CYP1A1/2, which might be of significance at least in those occupational situations where workers are exposured to higher diuron concentrations. The interspecies differences and interindividual variation were within the range of usual toxicokinetics default uncertainty/safety factors for chemical risk assessment. Our quantitative data on interspecies differences and individual variability may have an important contribution to diuron risk assessment. Fig. 1 . The overall scheme of the diuron metabolites detected in postmortem and hospitalized cases (Verheij et al., 1989; Van Boven et al., 1990) . In addition, the exact and calculated masses of diuron and N-demethyldiuron detected in the current study are shown. In the postmortem case (full line metabolic pathways) DCPMU was the major metabolite. In the hospitalized case (discontinuous line pathways) DCPU was the major metabolite in blood, while DCPMU was dominant in urine. * Modified and updated from Abass et al., (2007b) . 
FIGURE LEGENDS
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